Filing Analysis
C4 Therapeutics, Inc. held its Annual Meeting of Stockholders on June 24, 2026, reporting the results of four shareholder proposals including director elections and auditor ratification.
📋 Key Facts
- Elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors to hold office until 2029.
- Stockholders cast a non-binding advisory vote approving executive compensation (Say-on-Pay).
- Ratified KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Approved an amendment to the 2020 Stock Option and Incentive Plan regarding evergreen provisions and pre-funded warrants.
C4 Therapeutics presented clinical updates for its cemsidomide Phase 1/2 trial at the American Society of Hematology (ASH) Annual Meeting. The filing includes a press release and corporate presentation detailing data related to multiple myeloma and non-Hodgkin’s lymphoma.
📋 Key Facts
- Presented clinical update at ASH Annual Meeting on December 8, 2024.
- Reported Phase 1/2 trial data for cemsidomide in multiple myeloma and non-Hodgkin’s lymphoma.
- Published updated corporate presentation and press release via Exhibit 99.1, 99.2, and 99.3.
C4 Therapeutics, Inc. announced the appointment of Steven L. Hoerter to its Board of Directors on November 19, 2024. Mr. Hoerter will serve as a Class II director and has been granted stock options for up to 65,000 shares.
📋 Key Facts
- Steven L. Hoerter appointed as Director on November 19, 2024.
- Designated as a Class II director serving until the 2025 Annual Meeting of Stockholders.
- Board determined Mr. Hoerter is independent under Nasdaq listing standards.
- Granted stock options to purchase up to 65,000 shares of common stock under the 2020 Stock Option and Incentive Plan.
- Vesting schedule: One-third on the first anniversary; remainder vests quarterly over the subsequent two years.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results and business highlights for the period ended September 30, 2024.
📋 Key Facts
- The filing is a standard disclosure of quarterly results (Item 2.02).
- Financial results and business highlights were announced via press release on October 31, 2024.
- The report was signed by Kendra R. Adams, Chief Financial Officer.
C4 Therapeutics, Inc. announced the retirement of Chief Scientific Officer Dr. Stewart Fisher and the simultaneous appointment of Dr. Paige Mahaney as her successor. The filing is an amendment to a previous 8-K to correct dates regarding Dr. Fisher's retirement notification.
🚩 Red Flags
- Succession transition period involves a consulting agreement with the outgoing CSO that includes equity vesting through late 2025.
- Amendment filed to correct errors in the original filing regarding retirement notification dates.
📋 Key Facts
- Dr. Stewart Fisher notified the company of his intent to retire from the CSO role, effective when his successor joins (expected Oct 28, 2024).
- Dr. Fisher will serve as Senior Scientific Advisor through Dec 31, 2024, and a consultant/advisor through Dec 31, 2025.
- A Consulting Agreement was entered into on Oct 15, 2024; Dr. Fisher receives continued equity vesting through Dec 31, 2025 in exchange for advisory services.
- Dr. Paige Mahaney appointed as new CSO effective Oct 28, 2024, joining from Exelixis, Inc.
- Mahaney's compensation includes a $510,000 base salary, $150,000 sign-on bonus, and up to $75,000 relocation allowance.
- Material inducement for Mahaney includes an option to purchase 345,600 shares of common stock and 76,800 RSUs.
C4 Therapeutics announced a leadership transition in its scientific department, involving the retirement of Chief Scientific Officer Dr. Stewart Fisher and the appointment of Dr. Paige Mahaney as his successor.
🚩 Red Flags
- None identified; the departure is characterized as retirement without disagreement with management.
📋 Key Facts
- Dr. Stewart Fisher to retire as CSO effective October 28, 2024; will serve as Senior Scientific Advisor through Dec 31, 2024, and a consultant through Dec 31, 2025.
- Dr. Paige Mahaney appointed as new CSO, effective October 28, 2024.
- Dr. Mahaney joins from Exelixis, Inc., where she was SVP and Corporate Head of Drug Discovery.
- Mahaney's compensation includes a $510,000 base salary, $150,000 sign-on bonus, $75,000 relocation allowance, and performance bonuses up to 40%.
- Dr. Mahaney received a material inducement grant of up to 345,600 stock options and 76,800 RSUs.
C4 Therapeutics, Inc. announced an amendment to its 2020 Stock Option and Incentive Plan. The amendment restricts the Board's ability to reduce exercise prices or reprice options without prior stockholder approval.
📋 Key Facts
- Amendment No. 1 to the 2020 Stock Option and Incentive Plan was approved by the Board on October 7, 2024.
- The amendment prevents the Administrator from reducing exercise prices or repricing options through cancellation/re-grants without stockholder approval.
- The amendment is effective immediately and does not require stockholder approval.
C4 Therapeutics, Inc. announced the resignation of Director Malcolm Salter and the appointment of Stephen Fawell, Ph.D. to the Board effective August 29, 2024.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Malcolm Salter resigned from the Board effective August 29, 2024; no disagreements reported regarding company operations or policies.
- Stephen Fawell, Ph.D. appointed as a director and member of the Science and Technology Committee, designated as an independent Class III director.
- Dr. Fawell granted stock options for up to 65,000 shares under the 2020 Stock Option and Incentive Plan with a multi-year vesting schedule.
- Ronald Cooper appointed as chair of the Nominating and Corporate Governance (NCG) Committee; Bruce Downey appointed to the Audit Committee.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results and business highlights for the period ending June 30, 2024.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Financial results cover the quarter ended June 30, 2024.
- The report was signed by Kendra R. Adams, CFO and Treasurer on August 1, 2024.
C4 Therapeutics, Inc. held its Annual Meeting of Stockholders on June 20, 2024. The meeting resulted in the election of three Class I directors and the ratification of KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on June 20, 2024.
- Elected Kenneth Anderson, M.D., Laura Bessen, M.D., and Owen Hughes as Class I directors to hold office until 2027.
- Stockholders cast a non-binding advisory vote (Say-on-Pay) approving executive compensation with 34,500,552 votes 'For'.
- Ratified the selection of KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024.
C4 Therapeutics, Inc. announced a leadership reorganization within its Board of Directors, including the resignation of Glenn Dubin and the appointment of Ron Cooper as the new Chair of the Board.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Glenn Dubin resigned from the Board effective upon his successor's appointment; no disagreements were reported.
- Ron Cooper appointed to the Board as a Class II director, serving until the 2025 Annual Meeting.
- Ron Cooper appointed as the new Chair of the Board, replacing Bruce Downey who remains on the Board and NCG Committee.
- Mr. Cooper granted stock options for up to 65,000 shares under the 2020 Stock Option and Incentive Plan.
- Effective June 7, 2024: Ron Cooper appointed Chair; Bruce Downey stepped down as Chair but remains a Director.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2024.
📋 Key Facts
- The filing reports financial results and business highlights for the quarter ended March 31, 2024.
- The report was filed on May 8, 2024.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
C4 Therapeutics, Inc. announced the repricing of underwater stock options for several key executive officers and employees on March 7, 2024. The repricing aims to incentivize retention by lowering exercise prices to levels closer to historical highs or the IPO price.
🚩 Red Flags
- Related-party transaction involving the repricing of options for multiple executive officers.
- Significant gap between current stock price (implied by 'underwater' status) and previous exercise prices, indicating poor recent performance.
- Potential dilution/incentive misalignment: Repricing can be viewed as a way to compensate executives despite declining shareholder value.
📋 Key Facts
- Effective Date: March 7, 2024.
- Eligible Options: Those with an exercise price greater than $22.00 per share.
- Executive Repricing: CFO (Kendra Adams), CBO (Scott Boyle), CSO (Kelly Schick), Chief People Officer, and CLO (Jolie Siegel) had options repriced to $19.00 per share (IPO price).
- General Employee Repricing: Other employees had options repriced to $11.88 per share (52-week high).
- Retention Period: Options revert to original prices if the holder is terminated for cause, resigns (except death/disability), or exercises them before March 7, 2025.
- Exclusions: CEO Andrew Hirsch and non-employee Board members were not eligible for repricing.
C4 Therapeutics entered into a significant research collaboration and license agreement with Merck KGaA (EMD Serono) to discover two targeted protein degraders. The deal includes an upfront payment of $16 million and potential milestone payments totaling approximately $740 million.
🚩 Red Flags
- Merck KGaA retains the right to terminate the agreement for convenience upon 60 days' notice, which limits C4T's long-term control over the assets.
📋 Key Facts
- Entered into License Agreement with Merck KGaA (operating as EMD Serono in the U.S./Canada) on March 1, 2024.
- Merck KGaA to fund C4T's discovery research efforts and cover all development, regulatory, manufacturing, and commercialization costs.
- Upfront cash payment of $16.0 million from Merck KGaA to C4T.
- C4T eligible for up to ~$740 million in aggregate milestone payments (discovery, regulatory, and commercial).
- Royalty terms: mid-single digit to low-double digit percent on net sales.
- Merck KGaA has the right to terminate for convenience with 60 days' notice.
C4 Therapeutics, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ended December 31, 2023. The filing serves as a vehicle to distribute the company's earnings press release.
📋 Key Facts
- Reported date of earliest event: February 15, 2024
- Filing date: February 22, 2024
- Reporting period covered: Quarter and fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the press release with financial results.
C4 Therapeutics has furnished an investor presentation via Item 7.01, which includes forward-looking statements regarding the company's ongoing restructuring and cost-saving initiatives.
🚩 Red Flags
- Mention of an ongoing 'Restructuring' and associated charges/costs suggests significant operational changes or distress.
- Implicit focus on 'preserving cash runway' indicates a need for strict capital management.
📋 Key Facts
- Company posted an updated investor presentation to its website on January 11, 2024.
- The filing contains forward-looking statements concerning a 'Restructuring' process.
- Management expects the restructuring to preserve cash runway into 2027.
C4 Therapeutics announced a strategic restructuring involving a 30% reduction in workforce (approximately 45 positions) to optimize cost structure and focus on core clinical programs. The company expects to incur approximately $3 million in charges related to this restructuring, primarily in Q1 2024.
🚩 Red Flags
- Significant workforce reduction (30%) often indicates liquidity constraints or a pivot due to capital limitations.
- Immediate $3 million charge impact on upcoming quarterly earnings.
- Strategic shift suggests previous resource allocation was not meeting value creation goals.
📋 Key Facts
- Restructuring involves a reduction of approximately 30% of the workforce (45 positions).
- Estimated restructuring charges are approximately $3 million, mostly to be recognized in Q1 2024.
- The company is shifting focus to CFT7455 (Phase 1/2 clinical trial) and CFT1946 (Phase 1/2 clinical trial).
- Management expects the restructuring to preserve cash runway into 2027.
- Reductions are expected to be substantially complete by the end of Q1 2024.